SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGeron Corp.


Previous 10 Next 10 
To: Savant who wrote (3346)10/18/2012 8:20:02 PM
From: Savant
   of 3570
 
BioTime Proposes Buying Geron's Stem Cell Assets

Last Update: 10/18/2012 9:37:58 AM

By Saabira Chaudhuri

In an open letter, BioTime Inc. (BTX) urged Geron Corp. (GERN) shareholders to
push Geron's board to sell the company's stem cell assets to BioTime.

Geron's shares popped 7% to $1.52 in early trading.

In November of last year, Geron said it would discontinue the further development
of its stem cell programs and will eliminate 38% of its workforce as the company
aimed to focus resources on advancing two cancer drug candidates. At the time,
the company, which said it would eliminate 66 full-time positions, said it was
seeking partners with the technical and financial resources to further develop
its stem cell programs.

In its letter, BioTime said: "Nearly a year has now passed, and Geron has not
announced any transaction that would provide value to either Geron or its
shareholders from those stem cell assets."

Geron didn't immediately respond to a request for comment.

BioTime proposed that Geron would transfer its stem cell assets to a subsidiary
of BioTime, in exchange for which shareholders would receive a 21.4% stake in the
subsidiary.

BioTime said its offer, if accepted, would allow Geron shareholders to own up to
45% of a new publicly traded company that will own the Geron stem cell assets,
$40 million of BioTime stock, certain BioTime stem cell assets, and shares of
certain BioTime stem cell units.

Geron shareholders would also receive BioTime stock-purchase warrants presently
valued at about $13 million. Geron shareholders would continue to own the entire
Geron cancer therapy business through their ownership of Geron stock.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Savant who wrote (3347)10/18/2012 8:22:57 PM
From: Savant
   of 3570
 
BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation

ALAMEDA, Calif., Oct 18, 2012 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX)
today issued the following letter to the shareholders of Geron Corporation (GERN)
regarding Geron's stem cell assets:

October 18, 2012

AN OPEN LETTER TO GERON SHAREHOLDERS

Dear Geron Shareholders:

As you know, during November 2011, Geron Corporation (GERN) announced that it was
discontinuing its stem cell research and development programs and its clinical
trials of OPC-1, a groundbreaking product to treat spinal cord injuries
manufactured from human embryonic stem cells. Nearly a year has now passed, and
Geron has not announced any transaction that would provide value to either Geron
or its shareholders from those stem cell assets.

BioTime, Inc. (nyse mkt:BTX) is a publicly traded company engaged in research and
development of innovative new products in the field of regenerative medicine
utilizing stem cells and related technology. We are prepared to propose a
transaction between a recently formed, wholly owned subsidiary, BioTime
Acquisition Corporation (BAC), and Geron for the purpose of enabling BAC to put
the now dormant Geron stem cell assets back on track to speed the development and
commercialization of innovative new products to treat degenerative diseases.

Summary of Our Proposal

Our proposal includes two transactions, one which we call the "Stem Cell
Transaction" and one that we call the "Rights Offer" which are described in more
detail, along with other important information, in Appendix I: Details of Our
Proposal attached to this letter. Through these transactions, Geron shareholders
could own up to 45% of a new publicly traded company that will own the Geron stem
cell assets, $40 million of BioTime stock, certain BioTime stem cell assets, and
shares of certain BioTime stem cell subsidiaries. Geron shareholders would also
receive BioTime stock-purchase warrants presently valued at approximately $13
million. Geron would retain its cancer therapy business, including Imetelstat and
GRN1005, and its cash and short-term liquid investments and Geron shareholders
would continue to own 100% of the Geron cancer therapy business through their
ownership of Geron stock.

Through the Stem Cell Transaction, Geron would transfer its stem cell assets to
BAC, in exchange for which you along with the other Geron shareholders would
receive shares of BAC common stock representing approximately 21.4% of the
outstanding BAC capital stock. BioTime would contribute to BAC the following
assets in exchange for the balance of outstanding BAC capital stock:

-- $40 million in BioTime common shares;

-- Warrants to purchase BioTime common shares ("BioTime Warrants");

-- Rights to certain stem cell assets of BioTime, and shares of two BioTime
subsidiaries engaged in the development of therapeutic products from stem cells.

Through the "Rights Offer," BAC would seek to raise additional capital by
offering you and other Geron shareholders the opportunity to increase your
collective ownership interests in BAC to 45% by purchasing additional BAC shares,
if you choose to do so. In addition to acquiring BAC common stock in the Rights
Offer, if you exercise your subscription rights you would also receive warrants
to purchase additional BAC common stock, which if exercised would increase your
ownership in BAC. Those shareholders deciding not to purchase additional BAC
shares in the Rights Offering would have the opportunity to sell their rights at
prevailing market prices.

What You Can Do Now

BioTime and BAC cannot complete the Stem Cell Transaction as proposed without the
approval of Geron's Board of Directors. If you want the Geron Board of Directors
to pursue our proposal, we suggest that you contact the Geron Board and urge them
to work with BioTime and BAC management to negotiate a definitive agreement for
the Stem Cell Transaction. According to Geron's latest proxy statement, Geron
shareholders wishing to communicate with the Board of Directors, or with a
specific Board member, may do so by writing to the Board, or to the particular
Board member, and delivering the communication in person or mailing it to: Board
of Directors, c/o Stephen Rosenfield, Corporate Secretary, Geron Corporation,
currently located at 149 Commonwealth Drive, Menlo Park, CA 94025. Geron's proxy
statement represents that all mail addressed in this manner will be delivered to
the Chair or Chairs of the Committees with responsibilities touching most closely
on the matters addressed in the communication.

Very Truly Yours,
Michael D. West, PhDThomas Okarma, PhD, MD
Chief Executive OfficerChief Executive Officer
BioTime, Inc.BioTime Acquisition Corp.
Geron FounderFormer Geron CEO
Former Geron CEO(1999-2011)
(1990-1992)

Appendix I: Details of Our Proposal

The principal features of the Stem Cell Transaction and the Rights Offer are as
follows:

The Stem Cell Transaction

-- As a Geron shareholder, you would receive one BioTime Warrant and one share of
BAC Series A common stock for each 20 shares of Geron common stock you own. In
total, Geron shareholders would receive 21.4% of the BAC capital stock
outstanding at the consummation of the Stem Cell Transaction. BioTime would own
the remaining outstanding shares of capital stock of BAC. BioTime would also hold
BAC warrants that, if exercised, would increase BioTime's ownership interest by
approximately 2%.

-- Geron shareholders would receive BAC Series A common stock and BioTime would
own BAC Series B common stock. The BAC Series A common stock that you and other
Geron shareholders would acquire, and the BAC Series B common stock that will be
owned by BioTime, will be identical in almost all respects, except that having a
separate Series A common stock held by Geron shareholders will enable BAC to
distribute the BioTime Warrants, and to make the Rights Offer described below,
exclusively to the Series A shareholders.

-- BAC would seek to have the BAC Series A common stock received by Geron
shareholders listed for trading on a national securities exchange or on the OTC
Bulletin Board market if exchange listing is not feasible.

-- Following the acquisition of the Geron stem cell assets, BAC would distribute
the BioTime Warrants to the Geron shareholders as holders of BAC Series A common
stock. The distribution would entitle you and the other BAC Series A shareholders
to receive one BioTime Warrant for each BAC Series A share received in the Stem
Cell Transaction.

-- The BioTime Warrants and underlying BioTime common shares would be registered
under the Securities Act of 1933, as amended, and BioTime would seek to have the
BioTime Warrants listed for trading on the NYSE MKT where its common shares are
traded, or on the OTC Bulletin Board market if exchange listing is not feasible.

The Rights Offer

-- Under our proposal, after the Stem Cell Transaction, BAC, as a new public
company, would conduct a Rights Offer to the holders of the Series A common stock
to raise additional capital.

-- We presently contemplate that the Rights Offer would seek to raise
approximately $39 million and would provide the Geron shareholders with the
opportunity to increase their ownership interest in BAC to approximately 45% in
the aggregate (without taking into account any BAC warrants) if they continue to
hold their BAC Series A common stock and choose to exercise all of the
subscription rights they receive in the Rights Offer.

-- In addition to acquiring BAC Series A common stock, BAC shareholders who
exercise their subscription rights in the Rights Offer would also receive
warrants to purchase additional BAC Series A common stock, which if exercised
would increase Geron shareholders' ownership in BAC. We would propose to have BAC
list those warrants on a national securities exchange or to arrange for the
warrants to be traded on the OTC Bulletin Board so that the BAC shareholders
could also sell their warrants at prevailing market prices.

-- BAC would also seek to have the subscription rights distributed in the Rights
Offer listed for trading on a national securities exchange or over-the-counter
market so that shareholders who do not wish to exercise their subscription rights
could sell them at prevailing market prices.

-- If you receive subscription rights in the Rights Offer you would not be
obligated to exercise those subscription rights, but instead you may choose to
exercise some or all of your subscription rights in order to purchase additional
BAC Series A shares and warrants, or you may sell some or all of your
subscription rights, or you may simply choose to allow your subscription rights
to expire unexercised.

Other Requirements

In addition to Geron Board approval noted above, the approval of Geron
shareholders and BioTime shareholders may be required, depending on the structure
of the Stem Cell Transaction. Registration of the BAC shares under the Securities
Act of 1933, as amended (the "Securities Act"), will also be required. The Stem
Cell Transaction would be subject to a variety of conditions yet to be
negotiated. Further, the terms and conditions of the Rights Offer have not yet
been determined and the proposed Rights Offer will not be conducted until a
registration statement is filed under the Securities Act and becomes effective.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused
on regenerative medicine and blood plasma volume expanders. Its broad platform of
stem cell technologies is enhanced through subsidiaries focused on specific
fields of application. BioTime develops and markets research products in the
fields of stem cells and regenerative medicine, including a wide array of
proprietary ACTCellerate(TM) cell lines, HyStem(R) hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia(TM) (formerly known as
HyStem(R)-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix
for cell delivery in human clinical applications. BioTime's therapeutic product
development strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical need.
BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing
therapeutic products derived from stem cells for the treatment of retinal and
neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is
developing therapeutic applications of stem cells to treat orthopedic diseases
and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic
and therapeutic applications of stem cell technology in cancer, including the
diagnostic product PanC-Dx(TM) currently being developed for the detection of
cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of
BioTime's proprietary induced pluripotent stem cell technology to reverse the
developmental aging of human cells to treat cardiovascular and blood cell
diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards(R), the
leading human gene database, and is developing an integrated database suite to
complement GeneCards(R) that will also include the LifeMap(TM) database of
embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap will also market BioTime research
products. BioTime's lead product, Hextend(R), is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by
CJ CheilJedang Corporation under exclusive licensing agreements. Additional
information about BioTime can be found on the web at biotimeinc.com.

About BioTime Acquisition Corporation

BioTime Acquisition Corporation is a newly formed wholly owned subsidiary of
BioTime, Inc., through which BioTime plans to pursue opportunities and acquire
assets and businesses in the fields of stem cells and regenerative medicine.

This communication is not an offer to sell any securities or a solicitation of
any vote or approval and BioTime and BAC are not offering to sell, or soliciting
an offer to buy, any securities in any state where the offer or sale is not
permitted.

This communication is for informational purposes only and does not constitute an
offer to sell any shares of BAC common stock or warrants or a solicitation of any
vote or approval, nor is it a substitute for a prospectus/proxy statement that
may be included in a registration statement that may be filed with the Securities
and Exchange Commission (the "SEC") under the Securities Act with respect to the
proposed Stem Cell Transaction, or for a prospectus that may be included in a
registration statement that may be filed under the Securities Act with respect to
a Rights Offer. INVESTORS AND SECURITY HOLDERS OF GERON ARE URGED TO READ ANY
PROSPECTUS/PROXY STATEMENT FOR THE STEM CELL TRANSACTION AND ANY PROSPECTUS FOR
THE RIGHTS OFFER, AND ALL OTHER RELEVANT DOCUMENTS, THAT BIOTIME, BAC AND/OR
GERON MAY FILE WITH THE SEC, IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION. All documents referred to above, if filed by
BioTime or BAC, will be available free of charge at the SEC's website
Click for Detail

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: Savant10/19/2012 11:30:17 AM
   of 3570
 
Geron Board to Review BioTime's Offer to Buy Stem Cell Assets

Last Update: 10/19/2012 7:57:38 AM

By Melodie Warner

Geron Corp. (GERN) said its board will review BioTime Inc.'s (BTX) offer to buy
its stem cell assets.

The biopharmaceutical company said last November it would discontinue further
development of its stem cell programs and eliminate 38% of its workforce in order
to focus its resources on advancing two cancer drug candidates. At the time, the
company said it was seeking partners with the technical and financial resources
to further develop its stem cell programs.

Biotech company BioTime, in an open letter Thursday, urged Geron's shareholders
to push the company's board to sell its stem cell assets to BioTime.

BioTime proposed a two-part deal that could result in Geron shareholders owning
up to 45% of a new publicly traded company that owns the Geron stem cell assets,
$40 million of BioTime stock, certain BioTime stem cell assets, and shares of
certain BioTime stem cell subsidiaries. Geron shareholders would also receive
BioTime stock-purchase warrants presently valued at roughly $13 million.

Geron on Friday said it has considered a number of alternatives with respect to
its stem cell research and development programs.

Its board will review the BioTime proposal and "act in a manner that the board
believes is in the best interests of Geron's stockholders," the company said.

Shares of Geron and BioTime closed Thursday at $1.52 and $3.97, respectively.
Both stocks were inactive premarket.

Share RecommendKeepReplyMark as Last Read


From: Savant10/19/2012 4:44:14 PM
   of 3570
 
LifeMap Sciences, Inc. Announces Addition to Board of Directors and Provides
Update on Product Portfolio Development

ALAMEDA, Calif., Oct 19, 2012 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) and
its subsidiary, LifeMap Sciences, Inc., today announced the appointment of Louis
E. Silverman to LifeMap Sciences' board of directors.

Mr. Silverman is an experienced health care executive with board level and
operating experience in health care IT, pharmaceuticals, home health care,
worker's compensation managed care and revenue cycle management. From September
2009 through to its successful sale in June of 2012, Mr. Silverman was the Chief
Executive Officer of privately held Marina Medical Billing Service Inc., a
company focused on providing revenue cycle management services nationally to
emergency room physicians. Prior to joining Marina Medical, Mr. Silverman was
President and Chief Executive Officer of Lifecomm, Inc., a Qualcomm Incorporated
incubated wireless health services start-up. From 2000 - 2008, Mr. Silverman was
President and Chief Executive Officer of Quality Systems, Inc., a developer of
medical and dental practice management software, which he led to significant
revenue growth and an increase in market value from $42 million to $1.2 billion.
Previously, Mr. Silverman was the Chief Operations Officer of Corvel Corporation.
Mr. Silverman currently serves as a member of the Board of Directors of Questcor
Pharmaceuticals, Inc., a publicly traded biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Mr. Silverman also serves on the Board of Directors of
Comarco, Inc., a public company. Mr. Silverman earned a Bachelor of Arts degree
from Amherst College and a Masters in Business Administration from Harvard
Graduate School of Business Administration.

In addition, today LifeMap Sciences also announced progress on key development
initiatives. During the final quarter of the calendar year 2012, the company
expects to launch or upgrade its four database products: GeneCards(R), MalaCards,
PanDaTox, and LifeMap Discovery(TM). In addition, LifeMap Sciences will launch
the marketing and sales of BioTime's proprietary research product lines,
including PureStem(TM) human progenitor and human embryonic stem cell lines via
the company's LifeMap BioReagents(TM) portal. Another major LifeMap Sciences
initiative is its therapeutic discovery collaboration with BioTime, which
utilizes the LifeMap Discovery(TM) platform and leverages the LifeMap Sciences
scientific team (including ten Ph.D. and four M.S. biologists and bioinformatics
specialists) to research and identify those progenitor cell lines that are most
likely to be useful in developing cell-based regenerative medicine therapies for
a wide range of diseases. Once identified, selected cell lines will be marketed
by LifeMap Sciences for research purposes via the LifeMap BioReagents(TM) portal
and may be advanced into therapeutic development by BioTime and/or LifeMap
Sciences.

"Adding an experienced health care executive to our Board of Directors and
delivering meaningful enhancements to our product portfolio marks 2012 as a year
of great progress for our company and sets the stage for continued growth and
expansion into 2013," stated David Warshawsky, Ph.D., LifeMap Sciences' Chief
Executive Officer.

About LifeMap Sciences, Inc.

Share RecommendKeepReplyMark as Last Read


From: Savant11/15/2012 6:39:48 PM
   of 3570
 
BioTime and BioTime Acquisition Corporation Announce Combined $10 Million
Financing

ALAMEDA, Calif., Nov 15, 2012 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) and
its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly
announced today that they have entered into a non-binding letter of intent for a
$10 million investment from a private investor to provide financing for the
recently announced proposed acquisition of Geron Corp.'s stem cell assets by BAC.

Under the terms outlined in the letter of intent, the investor will invest $5
million in BioTime by purchasing 1.35 million BioTime common shares at a purchase
price of approximately $3.70 per share, and warrants to purchase 650,000
additional BioTime common shares with an exercise price of $5 per share and a
three year term.

In addition, the investor will contribute $5 million in cash to BAC in exchange
for shares of BAC common stock that, upon issuance, will represent approximately
7% of the BAC common stock then issued and outstanding, plus warrants to purchase
approximately 350,000 additional shares of BAC common stock at an exercise price
of $5 per share, with a three year term.

"This investment will provide BAC with financing to restart development of new
products and technologies from the soon to be acquired stem cell assets," stated
Michael West, PhD, Chief Executive Officer of BioTime, Inc.

"We are very pleased to receive such financial support from an investor who
shares our vision of the emerging field of regenerative medicine," said Thomas
Okarma, PhD, MD, BAC's Chief Executive Officer. "We look forward to the
opportunity to restart research and development and to continue the effort to
bring cell replacement therapies to the many patients who need them."

The letter of intent is not a binding agreement to complete the transactions.
Consummation of the transactions is subject to the investor entering into
definitive stock purchase agreements with BioTime and BAC, which agreements will
contain additional terms and conditions.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused
on regenerative medicine and blood plasma volume expanders. Its broad platform of
stem cell technologies is enhanced through subsidiaries focused on specific
fields of application. BioTime develops and markets research products in the
fields of stem cells and regenerative medicine, including a wide array of
proprietary ACTCellerate(TM) cell lines, HyStem(R) hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia(TM) (formerly known as
HyStem(R)-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix
for cell delivery in human clinical applications. BioTime's therapeutic product
development strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical need.
BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing
therapeutic products derived from stem cells for the treatment of retinal and
neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is
developing therapeutic applications of stem cells to treat orthopedic diseases
and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic
and therapeutic applications of stem cell technology in cancer, including the
diagnostic product PanC-Dx(TM) currently being developed for the detection of
cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of
BioTime's proprietary induced pluripotent stem cell technology to reverse the
developmental aging of human cells to treat cardiovascular and blood cell
diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards(R), the
leading human gene database, and is developing an integrated database suite to
complement GeneCards(R) that will also include the LifeMap(TM) database of
embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap will also market BioTime research
products. BioTime's lead product, Hextend(R), is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by
CJ CheilJedang Corporation under exclusive licensing agreements. Additional
information about BioTime can be found on the web at biotimeinc.com.

About BioTime Acquisition Corporation

BioTime Acquisition Corporation is a newly formed wholly owned subsidiary of
BioTime, Inc., through which BioTime plans to pursue opportunities and acquire
assets and businesses in the fields of stem cells and regenerative medicine.

This communication is for informational purposes only and does not constitute an
offer to sell any shares of BAC common stock or warrants or any BioTime common
shares or warrants. The BAC common stock and warrants and the BioTime common
shares and warrants may not be offered or sold in the United States absent
registration under the Securities Act of 1933, as amended, and or an applicable
exemption from registration requirements.

BioTime Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth
in research, technology, clinical development, and potential opportunities for
BioTime or BAC, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, uncertainty in the
results of clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties
that affect the business of BioTime or BAC, particularly those mentioned in
cautionary statements that are found in public filings with the Securities and
Exchange Commission, and other filings that BioTime or BAC may make with the
Securities and Exchange Commission. BioTime and BAC each disclaim any intent or
obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
phx.corporate-ir.net.

SOURCE: BioTime, Inc.

BioTime, Inc.
Peter Garcia, 510-521-3390, ext. 367
Chief Financial Officer
pgarcia@biotimemail.com
or
Judith Segall, 510-521-3390, ext. 301
jsegall@biotimemail.com

Share RecommendKeepReplyMark as Last Read


From: Savant12/3/2012 4:28:13 PM
   of 3570
 
Geron Discontinues GRN1005 and Restructures to Focus on Imetelstat Development in Hematologic Malignancies and Solid Tumors with Short Telomeres

Company to Host Conference Call at 8:30 a.m. ET on Tuesday, December 4

MENLO PARK, Calif., December 3, 2012 - Geron Corporation ( GERN) today announced that the company has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres. The company also announced a restructuring to reduce its workforce from 107 positions to 64 full-time positions, and to reduce its annual cash operating expenses from approximately $65 million in 2012 to approximately $33 million in 2013, which includes non-recurring costs of approximately $3 million associated with the restructuring and approximately $3 million for the discontinuation of clinical trials. The company expects to end 2012 with approximately $90 million in cash and investments.

Rationale for Discontinuing GRN1005
The decision to discontinue development of GRN1005 was made after the company completed a planned interim analysis for futility for GRABM-B, the company`s Phase 2 study in patients with brain metastases arising from breast cancer. This analysis showed that there were no confirmed intra-cranial responses, as determined by an Independent Review Facility, among the first 30 evaluable patients in the trial. Data from the analysis will be presented in a poster at the San Antonio Breast Cancer Symposium on December 6. In addition, the company is discontinuing GRABM-L, its Phase 2 study in patients with brain metastases arising from non-small cell lung cancer, because of the inability to successfully enroll the trial. Geron has provided to Angiochem, Inc. notice of termination of both the exclusive license agreement under which Geron received rights to GRN1005 and an associated research collaboration and option agreement.

"We are very disappointed that the results of the GRN1005 program fell short of our criteria for further development," said John A. Scarlett, M.D., Geron`s President and Chief Executive Officer. "Our immediate focus now is on the use of imetelstat in hematologic malignancies and solid tumors with short telomeres, which represent an opportunity for significant therapeutic advances and value creation."

Imetelstat Development in Hematologic Malignancies
Geron will be reporting the results of a phase 2 study of single agent imetelstat in patients with essential thrombocythemia (ET) in an oral presentation at the American Society of Hematology annual meeting on December 9. The ET study was designed to provide proof-of-concept for the potential use of imetelstat as a treatment for various hematologic myeloid malignancies, including myelofibrosis, myelodysplastic syndromes and acute myelogenous leukemias. JAK2 mutations are quantified during the trial to evaluate the effect of the drug on the malignant progenitor cells driving the disease. The top-line results from 14 patients enrolled in this study, all of whom were refractory to or intolerant of conventional therapies, showed a hematologic response rate of 100% (with 93% of patients achieving a complete response) and a molecular response rate of 86% among the seven patients who had a JAK2 mutation. These hematologic and molecular response rates, which exceeded the company`s expectations, suggest a selective inhibition of the malignant progenitor cells responsible for the patients` malignancy, and therefore potential disease-modifying activity by imetelstat that may be applicable in other hematologic myeloid malignancies.

Based on these results, Dr. Ayalew Tefferi, M.D., at the Mayo Clinic has begun an investigator-sponsored pilot study to evaluate safety and efficacy of imetelstat in patients with myelofibrosis, a myeloproliferative neoplasm in the same spectrum of diseases as ET. For more information about this study, please refer to http://clinicaltrials.gov/ct2/show/NCT01731951. The company is in the initial planning stages of a Geron-sponsored Phase 3-enabling study in myelofibrosis, which will be informed, in part, by data from the Mayo Clinic study. In addition, Geron intends to expand its directed program of investigator-sponsored trials in 2013 to other hematologic myeloid indications, including acute myelogenous leukemias.

Imetelstat Development in Solid Tumors Associated with Short Telomeres
Published non-clinical data have demonstrated that tumor cells with short telomeres are more sensitive to telomerase inhibition with imetelstat than tumor cells with longer telomeres. To evaluate this hypothesis clinically, Geron included a pre-specified sub-group analysis of results by tumor telomere length in its randomized Phase 2 trial of imetelstat in non-small cell lung cancer. In September 2012, Geron reported that an unplanned interim safety and efficacy analysis of the data from that trial suggested a modest but not statistically significant trend in progression-free survival in favor of the imetelstat treatment arm in the overall study population (hazard ratio = 0.78). However, the pre-specified sub-group analysis suggested that imetelstat-treated patients whose tumors had short telomeres at baseline experienced a clinically meaningful, statistically significant increase in progression-free survival compared to patients in the control arm (n = 19; hazard ratio = 0.32; p = 0.042), which was not observed in imetelstat-treated patients whose tumors had medium-to-long telomeres (n = 38; hazard ratio = 0.83; p = 0.62). The company expects to present the data from the full sub-group analysis at a scientific conference in 2013. The company is working on a refined assay to prospectively measure telomere length in individual patient tumor samples, which would be required if Geron conducts a Phase 3-enabling clinical study of the effect of imetelstat in patients with solid tumors that have short telomeres.

Management Changes
In connection with the restructuring, Graham Cooper, the company`s Chief Financial Officer, will be leaving the company to pursue other opportunities. Olivia Bloom, currently Vice President of Finance, Chief Accounting Officer and Treasurer, will assume the role of Chief Financial Officer effective December 7.

In addition, Geron has appointed Craig C. Parker, as Senior Vice President, Corporate Development and as a member of the executive management team, effective immediately. Mr. Parker has over 25 years experience in the science and business of the biotechnology industry, and was most recently Senior Vice President, Strategy and Corporate Development at Human Genome Sciences, Inc., until its sale to Glaxo SmithKline in 2012.

"I sincerely thank Graham for his many contributions to Geron`s programs, and wish him success in his future ventures," commented Dr. Scarlett. "I look forward to working with Olivia in her new role, for which she is highly qualified based on her many years of outstanding performance at the company, and I welcome Craig, whose extensive experience in business development and strategic analysis will complement our current team."

Conference Call
At 8:30 a.m. ET on December 4, 2012, Geron`s management will host a conference call to discuss the strategic realignment of the company.

Participants can access the conference call via telephone by dialing 866-713-8565 (U.S.); 617-597-5324 (international). The passcode is 32236649. A live audio-only webcast is also available at http://edge.media-server.com/m/p/t9tr3r34/lan/en. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast for 30 days.

About Geron

Geron is a biopharmaceutical company developing first-in-class therapies for cancer, including its telomerase inhibitor, imetelstat. For more information about Geron, visit www.geron.com

Share RecommendKeepReplyMark as Last Read


From: Savant12/10/2012 11:50:13 AM
   of 3570
 
Geron presents positive results from Phase 2 study of imetelstat in essential thrombocythemia at the American Society of Hematology Annual Meeting
Co announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54th Annual Meeting of the American Society of Hematology in Atlanta, GA. The results from the first 14 patients enrolled in the ET study were reported. All were refractory to or intolerant of conventional therapies (hydroxyurea, anagrelide and/or interferon-alpha). Platelet counts were reduced in all patients (a 100% hematologic response rate) and normalized in 13 out of 14 patients (a 92.9% complete response rate). The allelic burden of the JAK2 V617F gene mutation decreased over time in the seven patients who had such a mutation, with substantial reductions that qualified as partial molecular responses achieved in six out of seven (85.7%) patients within three to six months of treatment with imetelstat. In the study, imetelstat was generally well tolerated. The majority of the non- hematologic adverse events were mild-to-moderate in severity, the most frequent being gastrointestinal events.

Share RecommendKeepReplyMark as Last Read


From: tktrimbath12/31/2012 10:59:23 PM
   of 3570
 
My End of Year Review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron
GERN (market cap $0.184B)
Geron is a leading edge biotech specializing in critical treatments for the big medical issues: organ replacement and repair, cancer treatment, and such via telomerase, stem cells, nuclear transfers, and some novel chemistry. I liked their approach. They have been bold enough to pursue some of the most powerful biological technologies that many talk about, but few act upon. Despite their boldness, they have been conservative and cogniscent of public perception and federal regulations. Such medical advances can create great companies, but are high risk, cost more, and require longer clinical trials. If successful, their technological advantages may be hard to replicate or compete against.

Sadly, 2012 seemed to be the year of cancelled clinical trials. Geron finally got out of the lab and into the patient population, but for a variety of reasons they were not as successful as they, or I, had hoped. Diversification is important in risky ventures, and fortunately Geron has had more than only technology to pursue. Unfortunately, the list seems dramatically reduced. Good news is still possible, and there has been some, but the stock price attests that the news hasn't been significant enough within the investment community.

Failure in one set of trials does not change the odds of the other trials. I must remind myself of that.

DISCLOSURE LTBH since 1999 and continuing to hold. I won't buy more because 1) I have no discretionary funds (ask my mortgage company) and because I may have enough stock if they succeed (in which case I can pay off my mortgage company). Unfortunately, I may have to sell if I can't find a job or sell my house.
(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.wordpress.com)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tktrimbath who wrote (3354)1/1/2013 1:35:41 AM
From: mcbio
   of 3570
 
I had pretty much left GERN for dead. But their data with imetelstat against essential thrombocythemia ( ir.geron.com ) has me rethinking. Per recent CC, they have almost 3 years of cash and they believe imetelstat works in diseases with short telomeres (this may include myelofibrosis, which they are expanding testing into).

Share RecommendKeepReplyMark as Last Read


From: Savant1/7/2013 10:40:34 AM
   of 3570
 
BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets

Investor Commits to $10 Million Financing

ALAMEDA, Calif., Jan 07, 2013 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) and
its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly
announced today that they have entered into a definitive Asset Contribution
Agreement with Geron Corporation (GERN) to acquire the intellectual property,
including patents and patent applications, and other assets related to Geron's
human embryonic stem (hES) cell programs consistent with the financial terms
outlined in the letter of intent announced on November 15, 2012.

Under the definitive agreement, Geron will contribute to BAC intellectual
property, certain cell lines and other assets, including the Phase 1 clinical
trial of hES cell-derived oligodendrocytes in patients with acute spinal cord
injury, and Geron's autologous cellular immunotherapy program. BioTime will
contribute to BAC $5 million in cash, 8,902,077 BioTime common shares to be held
by BAC, five-year warrants to purchase 8,000,000 common shares of BioTime at a
price of $5.00 per share ("BioTime Warrants"), rights to use certain clinical
grade hES cell lines, a sublicense to use certain patents for stem cell
differentiation technology, and minority stakes in two of BioTime's subsidiaries,
OrthoCyte Corporation and Cell Cure Neurosciences Ltd. BAC will also pay to Geron
royalties on the sale of products that are commercialized, if any, in reliance
upon Geron patents contributed or licensed to BAC. A private investor has also
agreed to provide an equity investment of $5 million in BAC and a $5 million
equity investment in BioTime in conjunction with the transaction.

Geron pioneered the field of regenerative medicine in the mid-1990s by organizing
the first effort to isolate human embryonic stem (hES) cells. hES cells are
early-stage stem cells that are capable of becoming all of the cell types in the
human body, and therefore are widely recognized as a means of manufacturing cells
that are potentially useful in regenerating tissue function for a wide array of
degenerative diseases. Currently, Geron's hESC patent portfolio includes over 400
patents and patent applications that will be transferred or sublicensed to BAC.
Geron obtained the first approval from the Food and Drug Administration for human
clinical trials of a product manufactured from hES cells.

Geron's former hES cell programs included oligodendrocyte progenitor cells for
central nervous system disorders, cardiomyocytes for heart disease, pancreatic
islet cells for diabetes, dendritic cells as an immunotherapy vehicle, and
chondrocytes for cartilage repair. BAC may pursue the development of therapeutic
products from some or all of these cell types, depending upon a number of
factors, including the expected cost of development, sufficiency of financing,
the state of development of the technology acquired, regulatory considerations,
anticipated market size, and competition from other companies in the applicable
fields. BAC may also seek to develop other therapeutic products, taking into
account the same or other applicable considerations.

"Our consistent goal at BioTime has been to consolidate the pluripotent stem cell
technology platform," stated Michael West, Ph.D., Chief Executive Officer of
BioTime, Inc. "With this contribution of assets, the combined intellectual
property estate in the BioTime family of companies will be among the strongest in
the field of Regenerative Medicine; establishing our leadership in the industry
and advancing product development."

"We are excited about our approach toward consolidating the most important
technologies in Regenerative Medicine," said Thomas Okarma, M.D., Ph.D.,
president and CEO of BAC. "Regenerative Medicine holds great promise for patients
and now, with our significant collection of world class stem cell technologies,
IP, and experienced management, we are positioned to help realize that promise."

Closing of the transactions under the definitive agreement is subject to certain
negotiated closing conditions, including the registration of the BAC Series A
common stock, the BioTime common shares contributed to BAC, and the BioTime
Warrants under the Securities Act of 1933, as amended, and certain approvals by
BioTime shareholders. The transaction is expected to close no later than
September 30, 2013.

Upon closing of the transaction, Geron will receive BAC Series A common stock,
and BioTime and the private investor will receive BAC Series B common stock in
the transaction. The Series A and Series B common stock will be identical, except
that BAC will be entitled to make certain distributions or pay dividends on its
Series A common stock without making a distribution or paying a dividend on its
Series B common stock.

Following the closing of the transaction, Geron will distribute on a pro rata
basis to its stockholders the shares of BAC Series A common stock received in the
transaction. Following that distribution by Geron, BAC will distribute on a pro
rata basis to the holders of those shares the BioTime Warrants. The Series B
common stock will be convertible into Series A common stock following the
distribution of the BioTime Warrants.

Following these distributions, BioTime will own approximately 71.6%, Geron
stockholders will own approximately 21.4%, and the private investor will own
approximately 7.0%, of the outstanding BAC common stock. BioTime and the private
investor will also receive warrants to purchase additional shares of BAC Series B
common stock that would enable them to increase their collective ownership in BAC
by approximately 2.2%, which would reduce the Geron stockholders' ownership in
BAC to approximately 19.2%.

BAC plans to seek to list its Series A common stock, and BioTime intends to seek
to list the BioTime Warrants, on a national securities exchange.

In anticipation of use by BAC, BioTime is entering into a three-year lease of an
office and research facility in Menlo Park, Calif.

In a separate and related transaction, BioTime and BAC have each entered into
Stock and Warrant Purchase Agreements with a private investor to provide each
company with $5 million in equity financing. Under the terms of the BioTime
agreement, the investor will invest $5 million in BioTime by purchasing an
aggregate of 1,350,000 BioTime common shares at a purchase price of approximately
$3.70 per share and warrants to purchase 650,000 additional BioTime common shares
with an exercise price of $5.00 per share and a three year term. The shares and
warrants will be sold to the investor in two tranches. In the first tranche, the
investor will purchase 540,000 BioTime common shares and warrants to purchase
approximately 260,000 BioTime common shares for $2 million subject to the
conditions of the Stock and Warrant Purchase Agreement. The second BioTime
investment tranche of $3 million will be funded in conjunction with the closing
of the stem cell asset transaction with Geron. Closing of the second tranche of
the share and warrant purchase is subject to certain additional conditions; these
conditions include the closing of the stem cell asset transaction. This $5
million investment will be used to fund BioTime's $5 million cash contribution to
BAC.

Under the terms of its Stock Purchase Agreement with BAC, the investor will
contribute $5 million in cash to BAC in exchange for 2,136,000 shares of BAC
Series B common stock that, upon issuance, will represent approximately 7% of the
BAC common stock outstanding at the closing, plus warrants to purchase
approximately 350,000 additional shares of BAC Series B common stock at an
exercise price of $5.00 per share, with a three year term. Closing of the
financing in BAC will occur in conjunction with the closing of the stem cell
asset transaction with Geron, and is subject to certain conditions, including the
closing of the stem cell asset transaction.

Kaye Scholer LLP and Thompson, Welch, Soroko & Gilbert LLP are acting as legal
counsel to BioTime in connection with the transaction.

Additional Information and Where to Find It

All parties desiring details regarding the transaction are urged to review the
definitive agreement when it is available on the Securities and Exchange
Commission's (the "SEC's") website at sec.gov. In connection with the
proposed transaction, BioTime will file with the SEC a proxy statement, and plans
to file with the SEC other documents regarding the proposed transaction.
INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER
FILED DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Shareholders will be able
to obtain a free-of-charge copy of the proxy statement and other relevant
documents (when available) filed with the SEC from the SEC's website at
sec.gov. Shareholders will also be able to obtain a free-of-charge
copy of the proxy statement and other relevant documents (when available) by
directing a request by mail or email to BioTime's Chief Financial Officer at 1301
Harbor Bay Parkway, Alameda, California 94502 or pgarcia@biotimemail.com. BioTime
and Geron and certain of their respective directors and executive officers may,
under the rules of the SEC, be deemed to be "participants" in the solicitation of
proxies from shareholders of BioTime in favor of the share issuance and other
proposals in connection with the proposed transaction. Information regarding
BioTime's directors and executive officers is contained in BioTime's definitive
proxy statement filed with the SEC on April 30, 2012. Information about Geron's
directors and executive officers is set forth in Geron's proxy statement for its
2012 Annual Meeting of Stockholders, which was filed with the SEC on April 24,
2012. The proxy statement and other relevant documents (when available) filed
with the SEC are available free of charge with the SEC are available free of
charge at the SEC's website at sec.gov, and from Geron by contacting
Investor Relations by mail at Geron Corporation, 149 Commonwealth Drive, Suite
2070, Menlo Park, California 94025, Attn: Investor Relations Department, or by
going to Geron's Investor Relations page on its corporate website at
geron.com. Additional information regarding the interests of such
potential participants will be included in the proxy statement and the other
relevant documents filed with the SEC (when available).

This communication is for informational purposes only and does not constitute an
offer to sell any BAC common stock or warrants or any BioTime common shares or
warrants or a solicitation of any vote or approval, nor is it a substitute for a
prospectus that may be included in a registration statement that may be filed by
BAC or BioTime with the SEC under the Securities Act with respect to the proposed
transaction, or a proxy statement that will be provided to BioTime shareholders.
BioTime and BAC are not offering to sell, or soliciting an offer to buy, any
securities in any state where the offer or sale is not permitted.

About BioTime, Inc.

BioTime, headquartered in Alameda, Calif., is a biotechnology company focused on
regenerative medicine and blood plasma volume expanders. Its broad platform of
stem cell technologies is enhanced through subsidiaries focused on specific
fields of application. BioTime develops and markets research products in the
fields of stem cells and regenerative medicine, including a wide array of
proprietary PureStem(TM) cell lines, HyStem(R) hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia(TM) (formerly known as
HyStem(R)-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix
for cell delivery in human clinical applications. BioTime's therapeutic product
development strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical need.
BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing
therapeutic products derived from stem cells for the treatment of retinal and
neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is
developing therapeutic applications of stem cells to treat orthopedic diseases
and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic
and therapeutic applications of stem cell technology in cancer, including the
diagnostic product PanC-Dx(TM) currently being developed for the detection of
cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of
BioTime's proprietary induced pluripotent stem cell technology to reverse the
developmental aging of human cells to treat cardiovascular and blood cell
diseases. BioTime's subsidiary LifeMap Sciences, Inc., markets GeneCards(R), the
leading human gene database, and has developed an integrated database suite to
complement GeneCards(R) that includes the LifeMap Discovery(TM) database of
embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap is also marketing BioTime research
products. BioTime's lead product, Hextend(R), is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc., and in South Korea by
CJ CheilJedang Corporation under exclusive licensing agreements. Additional
information about BioTime can be found on the web at biotimeinc.com.

About BioTime Acquisition Corporation

BioTime Acquisition Corporation is a newly formed wholly owned subsidiary of
BioTime, Inc., through which BioTime plans to pursue opportunities and acquire
assets and businesses in the fields of stem cells and regenerative medicine.

BioTime Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates") should also be considered to be forward-looking
statements. Statements in this press release regarding BioTime or BAC's plans,
expectations or timing relating to BAC's acquisition of the stem cell assets and
related transactions are forward-looking statements and these statements involve
risks and uncertainties, including, without limitation, the ability of the
parties to close the transaction in a timely manner or at all, the possibility
that conditions to closing of the proposed transaction, including the approval of
BioTime's shareholders, and the effectiveness of registration statements to be
filed by BioTime and BAC with the SEC, may not be satisfied, as well as risks
inherent in the development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory approvals, need and
ability to obtain future capital, and maintenance of intellectual property
rights. Additional factors that could cause actual results to differ materially
from the results anticipated in these forward-looking statements are contained in
BioTime's periodic reports filed with the SEC under the heading "Risk Factors"
and and other filings that BioTime or BAC may make with the SEC. Undue reliance
should not be placed on these forward-looking statements which speak only as of
the date they are made, and the facts and assumptions underlying these statements
may change. Except as required by law, BioTime and BAC each disclaims any intent
or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
phx.corporate-ir.net.

SOURCE: BioTime, Inc.

BioTime, Inc.
Peter Garcia, 510-521-3390, ext. 367
Chief Financial Officer
pgarcia@biotimemail.com
or
Judith Segall, 510-521-3390, ext. 301
jsegall@biotimemail.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10